Effect of TRH analog (DN-1417) on tyrosine hydroxylase activity in mesocortical, mesolimbic and nigrostriatal dopaminergic neurons of rat brain

Effect of thyrotropin-releasing hormone on the locomotor and sensitizing effects of cocaine in rats

The present study was designed to find out whether single and repeated treatment with thyrotropin-releasing hormone (TRH) changed the cocaine-evoked hyperactivation or sensitization, and whether cross-sensitization occurred between TRH and cocaine. Like cocaine (10 mg/kg), TRH (10 mg/kg) increased the basal activation of rats; however, when given in combination with cocaine (10 mg/kg), TRH (5-10 mg/kg) did not change the locomotor effect of cocaine. On day 10, cocaine challenge of rats treated repeatedly with the psychostimulant (days 1-5) significantly enhanced locomotor hyperactivity compared to the effect of acute cocaine injection in saline-treated (days 1-5) animals. When co-administered with cocaine for 5 days during the development of sensitization, TRH (10 mg/kg) enhanced the effect of the challenge dose of cocaine (10 mg/kg) following a 5-day withdrawal. Given acutely with cocaine on day 10 to cocaine-treated animals, TRH (5-10 mg/kg) did not change the expression of cocaine sensitization. Significant enhancement of the locomotor response to TRH (10 mg/kg) challenge was observed in animals treated repeatedly with TRH. The response to TRH (5-10 mg/kg) was stronger in repeated cocaine-treated rats than in saline-injected ones; similarly, the response to cocaine (10 mg/kg) was more potent in TRH-treated animals compared to saline-injected ones (cross-sensitization). In conclusion, our results indicate that exposure to TRH induces sensitization to its locomotor hyperactivity effect. They also show that TRH enhances the development of cocaine sensitization, but affects neither the expression phase of the phenomenon nor the locomotor hyperactivity induced by a single dose of cocaine. Moreover, cross-sensitization between cocaine and TRH has also been demonstrated. These findings also may provide an insight into the relationship between TRH and cocaine in humans exposed to the psychostimulant.

YM-14673, a thyrotropin-releasing hormone analogue, injected into the nucleus accumbens and the striatum produces repetitive jaw movements in rats

Bilateral injections of the thyrotropin-releasing hormone (TRH) analogue, N alpha-[((S)-4-oxo-2-azetidinyl)-carbonyl]-L-histidyl-L-prolinamide dihydrate (YM-14673, 0.1 microgram and 1 microgram/0.2 microliters), into the nucleus accumbens, the dorsal and ventrolateral striatum produced repetitive jaw movements in a dose-dependent manner. The effects were greatest in the nucleus accumbens and smallest in the ventrolateral striatum. Pattern of the movements differed from that produced by injections of a mixture of SKF 38393 (5 micrograms) and quinpirole (10 micrograms); frequent tongue protrusions were evident in rats treated with the mixture but those were not seen in YM-14673-treated rats. TRH (1 microgram, 10 micrograms and 30 micrograms/0.2 microliters) did not evoke jaw movements from any of the sites. The non-selective dopamine receptor antagonist, cis-(Z)-flupentixol (10 micrograms), significantly reduced the response to administration of YM-14673 (1 microgram) into the nucleus accumbens or dorsal striatum, while the 5-hydroxytryptamine (5-HT)2A receptor antagonist, 2-(2-dimethylaminoethylthio)-3-phenylquinoline hydrochloride (ICI 169,369, 0.2 micrograms), did not affect the response to YM-14673 (1 microgram). Given intrathecally (0.5 microgram/5 microliters), both YM-14673 and TRH produced wet-dog shakes. Although the mechanisms giving rise to the display of jaw movements after intrastriatal injections of YM-14673 remain unknown, stimulation of the dopamine D1/D2 receptors may at least partly contribute to these effects. Anyhow, these mechanisms differ from that underlying the ability of YM-14673 and TRH to elicit wet-dog shakes, a mechanism that is known to involve serotonergic processes.

Specific binding of [3H]pGlu-3-Me-His-Pro-NH2 ([3H]MeTRH) to hypothalamic membranes of juvenile rainbow trout, Oncorhynchus mykiss

We investigated the existence and nature of specific [3H]pGlu-3-Me-His-Pro-NH2 ([3H]MeTRH) binding sites in juvenile rainbow trout (Oncorhynchus mykiss) hypothalamus. Washed hypothalamic membranes were incubated with [3H]MeTRH in the absence (B0) or presence of pGlu-His-Pro-NH2 (TRH) or MeTRH under various experimental paradigms; incubations were terminated by filtration and bound radioactivity was determined by liquid scintillation spectroscopy. Specific binding (Bsp) was tissue dependent, associable, dissociable, and thermolabile. Estimated rates of association (k+1) and dissociation (k-1) were 1.64 x 10(7) M-1 min-1 and 1.98 x 10(-2) min-1, respectively, providing a kinetically derived dissociation rate constant (Kd) of 1.21 x 10(-9) M. [3H]MeTRH binding was displaceable; LIGAND-analysis of three independent homologous displacement experiments consistently indicated a single class of binding sites with an average Kd = 6.91 (+/- 4.32) x 10(-9) M and average maximum binding capacity (Bmax) of 8.84 (+/- 2.72) x 10(-15) mol/mg protein. Native TRH also displaced the radiolabel in a dose dependent manner; LIGAND-estimates for Kd and Bmax were 1.52 (+/- 0.12) x 10(-9) M and 3.79 (+/- 0.99) x 10(-15) mol/mg protein (n = 3 experiments), respectively. Our data indicate that presence of a single class of specific high-affinity TRH-binding sites in the rainbow trout hypothalamus; these findings suggest a role for TRH in regulating the release of hypophysiotrophic factors in the teleost hypothalamus.

Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons is differentially regulated by reserpine

Tyrosine hydroxylase (TH)-mRNA, assayed by in situ hybridization combined with TH immunocytochemistry, showed a selective increase in the ventral tegmental area (A-10) but not in the substantia nigra (A-9) midbrain dopaminergic (DAergic) neurons 3 days after reserpine treatment. TH-mRNA in locus ceruleus noradrenergic (A-4) neurons was increased by reserpine, as confirmed by RNA blot hybridization. These findings show that TH-mRNA is differentially regulated in midbrain DAergic neurons in response to reserpine.

Neuropeptide-dopamine interactions. IV. Effect of thyrotropin-releasing hormone on striatal dopaminergic neurons

Many biologic effects of TRH seem to be mediated via a dopaminergic mechanism. The present study examined the effects of chronic TRH administration on the properties of nigrostriatal dopaminergic neurons. Ten days, continuous subcutaneous TRH administration via an osmotic minipump led to a significant rise in striatal level of 3,4-dihydroxyphenylacetic acid, but not of homovanillic acid or dopamine. These treatments also did not elicit any significant changes in the maximal binding capacity (Bmax) or affinity (KD) of either D1- or D2-dopamine receptor. By contrast, TRH administration led to a significant increase in both Bmax and KD of striatal mazindol binding. This effect of TRH, however, was not observed in in vitro studies. In conclusion, these data suggest that in vivo administration of TRH may modulate dopaminergic activities by altering, directly or indirectly, dopamine release and reuptake.